Back

Platelet C5aR1 mediates sex-specific ischemia-driven revascularization through estradiol-dependent CXCL4 release

Nording, H.; Baron, L.; Sauter, M.; Hagemann, L.; von Esebeck, J.; Schommer, N.; Duerschmied, D.; Marquardt, J.; Lerchenmueller, C.; Zuern, C.; Bibli, I.; Augustin, H.; Mueller, O. J.; Langer, H. F.

2026-06-27 immunology
10.64898/2026.06.25.732972 bioRxiv
Show abstract

Sex-specific differences in cardiovascular disease outcomes remain incompletely understood at the molecular level. Here, we identified the platelet complement receptor C5aR1 as a critical mediator of sex-specific revascularization following hindlimb ischemia through an estradiol-regulated mechanism. Ischemic tissue exhibited robust complement activation with C3b and C5a accumulation that correlated strongly with deposition of the anti-angiogenic factor CXCL4 (PF4). Mechanistically, C5a stimulation of platelets triggered CXCL4 secretion, and platelet-specific deletion of C5aR1 (using PF4-Cre-C5aR1fl/fl mice) significantly improved revascularization in male mice associated with decreased CXCL4 deposition, while sex-specific differences were not observed in cre-negative animals. Male mice exhibited substantially higher platelet C5aR1 expression and enhanced C5a-induced CXCL4 secretion compared to females, resulting in greater CXCL4 accumulation in the ischemic tissue. Importantly, estradiol stimulation of megakaryocytes suppressed C5aR1 expression during pro-platelet formation, uncovering a hormone-dependent regulatory mechanism. This estradiol-C5aR1-CXCL4 axis provides a molecular explanation for sex-specific differences in ischemic revascularization known from patient studies, as sex-specific deposition of the anti-angiogenic platelet-derived factor CXCL4 was C5aR1-dependent. These findings establish a novel and unexpected mechanistic link between sex hormones, a complement-platelet crosstalk and the angiogenic response to ischemia with potential clinical implications for sex-tailored therapeutic strategies.

Matching journals

The top 7 journals account for 50% of the predicted probability mass.

1
Nature Communications
5641 papers in training set
Top 16%
11.7%
2
Circulation Research
47 papers in training set
Top 0.1%
9.6%
3
Journal of Clinical Investigation
179 papers in training set
Top 0.5%
6.6%
4
Cell Reports
1498 papers in training set
Top 5%
6.6%
5
eLife
5828 papers in training set
Top 19%
6.1%
6
Proceedings of the National Academy of Sciences
2444 papers in training set
Top 8%
6.1%
7
Science Advances
1243 papers in training set
Top 6%
4.7%
50% of probability mass above
8
Journal of the American Heart Association
140 papers in training set
Top 2%
4.0%
9
Arteriosclerosis, Thrombosis, and Vascular Biology
71 papers in training set
Top 0.5%
3.2%
10
Nature Cardiovascular Research
33 papers in training set
Top 0.3%
3.2%
11
Circulation
74 papers in training set
Top 1.0%
3.2%
12
JCI Insight
277 papers in training set
Top 3%
2.7%
13
PLOS Biology
486 papers in training set
Top 3%
2.4%
14
Journal of Experimental Medicine
119 papers in training set
Top 1%
2.1%
15
Cardiovascular Research
37 papers in training set
Top 0.6%
1.9%
16
Atherosclerosis
30 papers in training set
Top 0.3%
1.9%
17
iScience
1154 papers in training set
Top 18%
1.7%
18
Scientific Reports
3612 papers in training set
Top 56%
1.7%
19
Cell Death & Disease
21 papers in training set
Top 0.3%
1.4%
20
Communications Biology
993 papers in training set
Top 23%
1.1%
21
PLOS ONE
5266 papers in training set
Top 56%
1.1%
22
The Journal of Immunology
166 papers in training set
Top 2%
1.1%
23
The FASEB Journal
194 papers in training set
Top 5%
1.0%
24
Advanced Science
286 papers in training set
Top 10%
0.8%
25
Frontiers in Immunology
638 papers in training set
Top 11%
0.6%
26
JACC: Basic to Translational Science
21 papers in training set
Top 1.0%
0.6%